Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aceprometazine is a phenothiazine derivative with neuroleptic, sedative, antihistamine, and antiemetic properties. It primarily functions by blocking dopamine D2 receptors in the brain, which contributes to its antipsychotic and sedative effects. Additionally, it acts as an antihistamine by blocking histamine H1 receptors, providing sedative and anti-allergy benefits. The drug also exhibits anticholinergic effects, which can reduce secretions and muscular spasms, and its comprehensive receptor blockade aids in mitigating nausea and vomiting. While it has been used in human medicine for conditions such as anxiety, depression, and sleep disorders (often in combination with meprobamate), its use in humans has become less frequent due to the availability of newer drugs with more favorable side effect profiles. It is also used in veterinary medicine. Aceprometazine can be administered orally, intramuscularly, and intravenously.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Aceprometazine.